GT 719
Alternative Names: GT-719Latest Information Update: 30 May 2025
At a glance
- Originator GRIT Biotechnology
- Class Antineoplastics; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 18 Apr 2025 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Recurrent) in China (Parenteral) (NCT06948981)
- 18 Apr 2025 Phase-I/II clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, Recurrent) in China (Parenteral) (NCT06948981)